Literature DB >> 15925109

LRRK2 R1441G in Spanish patients with Parkinson's disease.

Ignacio F Mata1, Julie P Taylor, Jennifer Kachergus, Mary Hulihan, Cecilia Huerta, Carlos Lahoz, Marta Blazquez, Luis M Guisasola, Carlos Salvador, Renee Ribacoba, Carmen Martinez, Matthew Farrer, Victoria Alvarez.   

Abstract

Pathogenic mutations in leucine-rich repeat kinase 2 (LRRK2; PARK8) have been implicated in autosomal dominant, late-onset Parkinson's disease (PD). The LRRK2 4321C>G (R1441G) mutation was originally identified in Spanish families originating from the Basque region. Within this ethnicity, Lrrk2 R1441G substitutions have been suggested as a frequent cause of disease. Herein we have assessed another referral-based series of 225 patients with PD from the neighboring region of Asturias, Northern Spain. The LRRK2 4321C>G mutation was found in 5 (2.7%) of sporadic, late-onset patients and was not present in control subjects. Although patients with a Lrrk2 R1441G substitution are apparently unrelated, they share a chromosome 12q12 haplotype not found in controls and indicative of a common founder.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925109     DOI: 10.1016/j.neulet.2005.03.033

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  19 in total

Review 1.  Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression.

Authors:  Jaclyn Nicole Le Grand; Laura Gonzalez-Cano; Maria Angeliki Pavlou; Jens C Schwamborn
Journal:  Cell Mol Life Sci       Date:  2014-11-18       Impact factor: 9.261

2.  Lrrk2 pathogenic substitutions in Parkinson's disease.

Authors:  Ignacio F Mata; Jennifer M Kachergus; Julie P Taylor; Sarah Lincoln; Jan Aasly; Timothy Lynch; Mary M Hulihan; Stephanie A Cobb; Ruey-Meei Wu; Chin-Song Lu; Carlos Lahoz; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2005-09-17       Impact factor: 2.660

Review 3.  PARK8 LRRK2 parkinsonism.

Authors:  Kristoffer Haugarvoll; Zbigniew K Wszolek
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

4.  Lrrk2 mutations in South America: A study of Chilean Parkinson's disease.

Authors:  Carolina Perez-Pastene; Stephanie A Cobb; Fernando Díaz-Grez; Mary M Hulihan; Marcelo Miranda; Pablo Venegas; Osvaldo Trujillo Godoy; Jennifer M Kachergus; Owen A Ross; Luis Layson; Matthew J Farrer; Juan Segura-Aguilar
Journal:  Neurosci Lett       Date:  2007-06-17       Impact factor: 3.046

5.  Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.

Authors:  Taku Hatano; Manabu Funayama; Shin-Ichiro Kubo; Ignacio F Mata; Yutaka Oji; Akio Mori; Cyrus P Zabetian; Sarah M Waldherr; Hiroyo Yoshino; Genko Oyama; Yasushi Shimo; Ken-Ichi Fujimoto; Hirokazu Oshima; Yasuto Kunii; Hirooki Yabe; Yoshikuni Mizuno; Nobutaka Hattori
Journal:  Neurobiol Aging       Date:  2014-06-02       Impact factor: 4.673

6.  The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.

Authors:  Soumya Ray; Samantha Bender; Stephanie Kang; Regina Lin; Marcie A Glicksman; Min Liu
Journal:  J Biol Chem       Date:  2014-04-02       Impact factor: 5.157

Review 7.  ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.

Authors:  Manish Verma; Erin K Steer; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2013-11-10

8.  Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain.

Authors:  Ignacio F Mata; Carolyn M Hutter; María C González-Fernández; Marian M de Pancorbo; Elena Lezcano; Cecilia Huerta; Marta Blazquez; Renee Ribacoba; Luis M Guisasola; Carlos Salvador; Juan C Gómez-Esteban; Juan J Zarranz; Jon Infante; Joseph Jankovic; Hao Deng; Karen L Edwards; Victoria Alvarez; Cyrus P Zabetian
Journal:  Neurogenetics       Date:  2009-03-24       Impact factor: 2.660

9.  Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.

Authors:  Nicole Bryant; Nicole Malpeli; Julia Ziaee; Cornelis Blauwendraat; Zhiyong Liu; Andrew B West
Journal:  Hum Mol Genet       Date:  2021-04-30       Impact factor: 6.150

10.  Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.

Authors:  Chen Yao; William M Johnson; Yue Gao; Wen Wang; Jinwei Zhang; Maria Deak; Dario R Alessi; Xiongwei Zhu; John J Mieyal; Hanno Roder; Amy L Wilson-Delfosse; Shu G Chen
Journal:  Hum Mol Genet       Date:  2012-10-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.